semaglutide weight loss fda approval Novo Nordisk's weight-loss pill wins FDA approves obesity drug that

Adverse effects such as nausea and digestive issues were more common among participants taking GLP-1 drugs, and data on cardiovascular outcomes, mortality, and quality of life remain uncertain

Data availability The DNA methylation data generated in this study for longitudinal semaglutide and placebo samples, have been deposited in the GEO database under accession number: GSE327270

Vitamin B6 metabolism in microbes and approaches for fermentative production

Co-medication analysis A case-by-case analysis was performed by two independent pharmacists to identify the combined medications by searching DRUG and THER files of the included 204 cases